CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration

Sára Mravinacová,Vilma Alanko,Sofia Bergström,Claire Bridel,Yolande Pijnenburg,Göran Hagman,Miia Kivipelto,Charlotte Teunissen,Peter Nilsson,Anna Matton,Anna Månberg

DOI: https://doi.org/10.1186/s13024-024-00705-z

2024-02-15

Molecular Neurodegeneration

Abstract:Amyloid and tau aggregates are considered to cause neurodegeneration and consequently cognitive decline in individuals with Alzheimer's disease (AD). Here, we explore the potential of cerebrospinal fluid (CSF) proteins to reflect AD pathology and cognitive decline, aiming to identify potential biomarkers for monitoring outcomes of disease-modifying therapies targeting these aggregates.

neurosciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to find cerebrospinal fluid (CSF) protein markers or protein pairs that can more effectively reflect the pathological changes and cognitive decline in Alzheimer's disease (AD). Specifically, the study aims to identify potential biomarkers or protein pairs that can be used to monitor the effects of disease - modifying therapies targeting amyloid and tau protein aggregation by measuring and analyzing the levels of 49 pre - selected proteins in the Swedish Memory Clinic Cohort and the Amsterdam Dementia Cohort.

### Research Background
Alzheimer's disease is a neurodegenerative disease, and its pathological features are the accumulation of amyloid - beta (Aβ) plaques and tau protein tangles in the brain. These aggregates are considered to be the causes of neurodegeneration and cognitive function decline. Currently, although some antibody therapies have been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) has not yet approved any disease - modifying therapies. Therefore, it is particularly important to develop biomarkers that can effectively monitor the effects of these therapies.

### Research Methods
The researchers used a multiplex antibody - based suspension bead array technology to measure the levels of 49 proteins in CSF. The study subjects included 148 amyloid - beta and tau - negative individuals (A - T - ) and 65 amyloid - beta and tau - positive individuals (A + T + ). In addition, there was an independent validation cohort, which included 26 A - T - and 26 A + T + individuals. Through support vector machine modeling, the researchers attempted to find protein pairs that could better reflect AD pathology and cognitive decline.

### Main Findings
1. **Protein Clustering**:
- The study found that the 49 proteins could be divided into two main clusters: one was strongly correlated with t - tau and p - tau (tau - related group), and the other was strongly correlated with Aβ42 (amyloid - related group).
- The tau - related group included 11 proteins, such as NRGN, GAP43 and SNCB, and these proteins were significantly elevated in AD patients.
- The amyloid - related group included 16 proteins, such as PTPRN2, NCAN and CHL1.

2. **Predictive Ability of Protein Pairs**:
- Support vector machine modeling showed that protein pairs from different clusters had significantly higher accuracy in distinguishing A - T - and A + T + individuals than single proteins or protein pairs from the same cluster.
- Combining tau - related proteins with amyloid - related proteins into ratios could significantly improve their correlation with cognitive decline.

### Conclusion
Combining brain - derived proteins from different clusters can greatly enhance their ability to distinguish individuals affected and unaffected by AD pathology and their correlation with cognitive decline. This finding may help adjust the inter - individual variability and provide new biomarkers for monitoring the effects of AD disease - modifying therapies.

### Keywords
Alzheimer's disease, cerebrospinal fluid, neurodegeneration, cognitive decline, protein ratio, protein profile, affinity proteomics, inter - individual variability